Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase 3 1

Status

Completed 12Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × STA 9090 × Clear all
NCT01551693 2017-04-12

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
15 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡